Trade

with

Omeros Corp
(NASDAQ: OMER)
AdChoices
11.76
-0.37
-3.01%
After Hours :
11.76
0.00
0.00%

Open

12.08

Previous Close

12.12

Volume (Avg)

249.44k (292.98k)

Day's Range

11.75-12.38

52Wk Range

6.92-18.80

Market Cap.

412.03M

Dividend Rate ( Yield )

-

Beta

1.12

Shares Outstanding

34.00M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 1.60M

    • Net Income

    • -39.80M

    • Market Cap.

    • 412.03M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -9,872.16

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.12

    • Forward P/E

    • -35.09

    • Price/Sales

    • 769.23

    • Price/Book Value

    • -38.76

    • Price/Cash flow

    • -10.96

      • EBITDA

      • -37.13M

      • Return on Capital %

      • -157.21

      • Return on Equity %

      • -

      • Return on Assets %

      • -157.21

      • Book Value/Share

      • -0.31

      • Shares Outstanding

      • 34.00M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 34.00

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -0.34

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -67.90

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 6.46

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -9,872.16

            • 39.38

            • Net Profit Margin

            • -9,872.16

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -1,321.30

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 3.20

              • 2.92

              • Quick Ratio

              • 3.10

              • 2.35

              • Interest Coverage

              • -16.98

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -0.31

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -8.22

                • 196.08

                • P/E Ratio 5-Year High

                • -11.67

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.96

                • 124.82

                • Price/Sales Ratio

                • 833.33

                • 9.12

                • Price/Book Value

                • -42.37

                • 8.26

                • Price/Cash Flow Ratio

                • -10.96

                • 47.39

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -157.21

                        (-102.30)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.02

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -50.52M
                      Operating Margin
                      -3,157.25
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -10.96
                      Ownership

                      Institutional Ownership

                      46.47%

                      Top 10 Institutions

                      31.12%

                      Mutual Fund Ownership

                      16.46%

                      Float

                      93.16%

                      5% / Insider Ownership

                      5.85%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • SPDR® S&P Pharmaceuticals ETF

                      •  

                        761,827

                      • 0.00

                      • 2.43

                      • iShares Russell 2000 (AU)

                      •  

                        523,601

                      • -1.01

                      • 1.67

                      • Vanguard Total Stock Mkt Idx

                      •  

                        517,793

                      • 0.00

                      • 1.52

                      • iShares Nasdaq Biotechnology

                      •  

                        451,295

                      • -0.69

                      • 1.44

                      • Candriam Eqs L Biotechnology

                      •  

                        415,000

                      • -7.37

                      • 1.22

                      • Vanguard Extended Market Index Fund

                      •  

                        294,192

                      • 2.64

                      • 0.87

                      • iShares Russell 2000 Growth

                      •  

                        226,921

                      • -2.72

                      • 0.73

                      • Tocqueville Fund

                      •  

                        175,000

                      • 0.00

                      • 0.51

                      • Mutual of America Small Cap Growth

                      •  

                        133,589

                      • -6.33

                      • 0.39

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        108,585

                      • 0.00

                      • 0.32

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Ingalls & Snyder LLC

                      •  

                        2,066,279

                      • +16.88%

                      • 6.08

                      • Tocqueville Asset Management L.P.

                      •  

                        1,518,989

                      • +20.09%

                      • 4.47

                      • BlackRock Fund Advisors

                      •  

                        1,249,271

                      • -4.37%

                      • 3.67

                      • Cormorant Asset Management, LLC

                      •  

                        1,123,000

                      • +124.60%

                      • 3.30

                      • Vanguard Group, Inc.

                      •  

                        938,532

                      • +1.74%

                      • 2.76

                      • Baker Bros Advisors LLC

                      •  

                        753,804

                      • 0.00%

                      • 2.22

                      • State Street Corp

                      •  

                        466,906

                      • +5.57%

                      • 1.37

                      • Candriam Luxembourg

                      •  

                        415,000

                      • -7.37%

                      • 1.22

                      • Northern Trust Investments, N.A.

                      •  

                        379,680

                      • -3.50%

                      • 1.12

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Slow Growth

                      Style

                      Small Core

                      Omeros Corp is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system. Its product OMS302 or Omidria completed its Phase 3 c...morelinical trial is used for lens replacement surgery and is derived from its PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. In November 2013, the FDA conditionally accepted Omidria as the proposed brand name for OMS302 in the U.S. and in December 2013, the EMA accepted Omidria as the proposed brand name for OMS302 in the EU. In addition to Omidria, the Company has other development programs for pain, inflammation, coagulopathies and disorders of the ...morecentral nervous system. It has six clinical-stage programs in its pipeline; OMS103 for inflammatory pain following arthroscopic partial meniscectomy surgery, which has completed one Phase 3 trial, its PDE10 inhibitor OMS824 for schizophrenia, which is in a Phase 2 clinical program for patients with stable schizophrenia, its PDE10 inhibitor OMS824 for Huntington's disease, which is in Phase 2 clinical program, its MASP-2 antibody OMS721 for the treatment of thrombotic microangiopathies, which has completed dosing in Phase 1 clinical trial and a Phase 2 clinical program is underway, its PPAR? program, in which three Phase 2 clinical trials are being conducted by its collaborators to evaluate a PPAR? agonist, alone or in combination with other agents, for treatment of addiction to opioids and to nicotine and its PharmacoSurgery product OMS201 for use during urological procedures, including uroendoscopic procedures, that has completed a Phase 1/Phase 2 clinical trial in 2010 and is not currently in active clinical trials. As of February 15, 2014, the Company owned or held licenses to a total of 51 issued or allowed patents and 51 pending patent applications in the U.S. and 245 issued or allowed patents and 230 pending patent applications in foreign markets. The Company is subject to regulate under the U.S. and EU governing regulations.lessless

                      Key People

                      Dr. Gregory A. Demopulos,M.D.

                      CEO/Chairman of the Board/Director/Founder/President

                      Mr. Michael Jacobsen

                      CFO/Chief Accounting Officer/Vice President, Divisional

                      Timothy M. Duffy

                      Vice President, Divisional

                      Michael K. Inouye

                      Vice President, Divisional

                      Ms. Marcia S. Kelbon

                      General Counsel/Secretary/Vice President, Divisional

                      • Omeros Corp

                      • 201 Elliott Avenue West

                      • Seattle, WA 98119

                      • USA.Map

                      • Phone: +1 206 676-5000

                      • Fax: -

                      • omeros.com

                      Incorporated

                      1994

                      Employees

                      75

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: